Topics
Gliomas | Treatment | Clinical trials | Crelosidenib/LY3410738
Home > Publications > Topics > Gliomas > Treatment > Clinical trials > Crelosidenib
IDH1-mutant glioma
Harding JJ, Oh DY, Mercade TM, Goyal L, Varkaris A, Palmieri LJ,
Ikeda M, Kondo S, Bai LY, Ueno M, Chen LT, Papadopoulos KP, Shroff
RT, Kizilbash SH, Hollebecque A, Adeva J, Cosman R, Yokota T, Park
JO, Turk A, Liao CY, Satoh T, Borad MJ, El-Khoueiry A, Azad N,
Jaeckle KA, Loong HH, Yong WP, Bender MH, Varughese SC, Sachdeva
D, Radtke DB, Gueorguieva I, Szpurka AM, Chen HR, Liu H, Xu X,
Rodon J.
Final Results from a
First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase
(IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring
IDH1 or IDH2 Mutations.
Clin
Cancer Res. 2025 Sep 30. doi:
10.1158/1078-0432.CCR-25-0174. PMID:
41026608. Interventional
study˰ ˍ